Try a new search

Format these results:

Searched for:

person:charyd01 or goldfd01 or alin06 or bearal01 or benstj01 or caplin01 or chawlh01 or kaploe01 or kalacs01 or katzl01 or kaufmj10 or langsc01 or liud03 or lowenj01 or mattoa02 or mehtam02 or michaj02 or moderf01 or nazzal01 or scherj02 or skolne01 or soomri01 or tatapv01 or thompn01 or weissj02 or zhdano01 or cohene16 or meg271

active:yes

exclude-minors:true

Total Results:

1246


Preventing chronic kidney disease and maintaining kidney health: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Ortiz, Alberto; Arreola Guerra, José Manuel; Chan, Juliana C N; Jha, Vivekanand; Kramer, Holly; Nicholas, Susanne B; Pavkov, Meda E; Wanner, Christoph; Wong, Leslie P; Cheung, Michael; King, Jennifer M; Grams, Morgan E; Jadoul, Michel; Tuttle, Katherine R; ,
To date, the primary focus of chronic kidney disease (CKD) care has been on managing disease progression, complications, and kidney failure. In contrast, maintaining kidney health and preventing CKD have received limited attention, despite their potential to save millions of lives, reduce health care costs, and lessen environmental burdens. The cardiovascular-kidney-metabolic (CKM) concept frames CKD as part of a complex, high-risk syndrome requiring global risk assessment and multifactorial intervention. CKD incidence along with CKM risk factors may be reduced by a healthy diet, physical activity, and a supportive environment. However, risk for CKD does extend beyond the cardiovascular-metabolic component, and residual risk persists despite healthy lifestyles and treatment of risk factors. Post hoc analyses of clinical trials suggest pharmacological interventions, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, may help to prevent or regress CKD in individuals with type 2 diabetes or obesity. Clinical trials are needed to validate these findings in broader high-risk populations. Personalized strategies to improve kidney health should include CKD risk prediction via targeted testing, genetic or biomarker assessments, shared decision-making, cost considerations, selection of therapeutics, and the potential for adverse effects. The overall goals of CKD prevention should prioritize a lifespan approach to risk evaluation along with safe, efficacious, and accessible interventions to maintain kidney health.
PMID: 40536455
ISSN: 1523-1755
CID: 5871192

Titration and discontinuation of semaglutide for weight management in commercially insured US adults

Xu, Yunwen; Carrero, Juan J; Chang, Alexander R; Inker, Lesley A; Zhang, Donglan; Mukhopadhyay, Amrita; Blecker, Saul B; Horwitz, Leora I; Grams, Morgan E; Shin, Jung-Im
OBJECTIVE:The objective of this study is to examine real-world dose titration patterns of semaglutide for weight management (Wegovy, Novo Nordisk A/S) in US adults and identify characteristics associated with early discontinuation. METHODS:We identified 15,811 commercially insured adults who started semaglutide for weight management (administrated through single-dose prefilled pens) between June 2021 and December 2023. We depicted dose-titration patterns over 5 months and identified factors associated with discontinuation using multivariable Cox regression. Sensitivity analyses examined patterns after supply shortage resolution (after October 2023). RESULTS:Most semaglutide users deviated from the recommended monthly dose-escalation schedule within the first 5 months. By the fifth month, nearly one-half (46%) had discontinued the treatment, with similar rates (48%) among those initiating after supply stabilization. Discontinuation was strongly associated with copayment amount, with rates increased from 41% in the lowest quintile ($1-$54 per month) to 51% in the highest quintile ($161-$1460 per month). Higher discontinuation rates were also associated with lower household income and education level. CONCLUSIONS:The deviations from the recommended dose-escalation schedule and high discontinuation rate among real-world semaglutide users indicate important challenges in the delivery of evidence-based care. Policy interventions that reduce financial barriers to the persistence of semaglutide are needed.
PMID: 40464214
ISSN: 1930-739x
CID: 5862372

Corrigendum to "Effects of dialysate potassium concentration of 3.0 mmol/l with sodium zirconium cyclosilicate on dialysis-free days versus dialysate potassium concentration of 2.0 mmol/l alone on rates of cardiac arrhythmias in hemodialysis patients with hyperkalemia." Kidney International 2025;107:169-179

Charytan, David M; Winkelmayer, Wolfgang C; Granger, Christopher B; Middleton, John P; Herzog, Charles A; Chertow, Glenn M; Eudicone, James M; Whitson, Jeremy D; Tumlin, James A; ,
PMID: 40404254
ISSN: 1523-1755
CID: 5853512

Questionable role of opioids for analgesia in renal colic and its urological interventions

Krieger, Anna; Zaidan, Nadim; Zhao, Philip; Borin, James F; Goldfarb, David S
OBJECTIVES/UNASSIGNED:To review the different analgesic modalities and benefits of non-opioid pain management options as well as their evidence-based, established superiority, compared to opioid medications. MATERIALS/UNASSIGNED:We review the updated literature about pain management of renal colic, a prevalent and painful urologic condition. Prescribers must know the efficacy, safety and possible ramifications of analgesic selections. RESULTS/UNASSIGNED:Commonly prescribed medications in the United States (US) include non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and opioids. In the context of the current epidemic of death from overdoses of opioids in the US, the frequency of opioid prescribing for renal colic is likely excessive, problematic and potentially remediable. We also present analgesic modalities revolving around interventions with peri-procedural pain management for ureteroscopy and percutaneous nephrolithotomy. After touching on the implications of misguided opioid use, especially in the context of kidney stone disease, and despite the evidence and consensus guidelines supporting NSAIDs in renal colic, current evidence has shown that many clinicians continue to prescribe opioids as first-line treatment. Finally, we highlight current efforts targeted at the reduction of opioid use and prescription in the setting of provider education and decision aids in curbing misguided opioid use in renal colic. CONCLUSIONS/UNASSIGNED:While the evidence against treating kidney stones with opioids is clear, more work is needed to shift current practices to reflect that renal colic is a non-opioid-requiring condition.
PMCID:12152362
PMID: 40503371
ISSN: 2688-4526
CID: 5869472

Trends in obesity and glucagon-like peptide-1 receptor agonist prescriptions in type 1 diabetes in the United States

Xu, Yunwen; Echouffo Tcheugui, Justin B; Coresh, Josef; Grams, Morgan E; Selvin, Elizabeth; Fang, Michael; Shin, Jung-Im
AIMS/OBJECTIVE:To characterize trends in obesity and prescriptions for glucagon-like peptide-1 receptor agonists (GLP-1RAs) across body mass index (BMI) categories among US youth and adults with type 1 diabetes (T1D) from 2008 to 2023. MATERIALS AND METHODS/METHODS:Patients with T1D were identified using a validated algorithm using de-identified electronic health record (EHRs) data from 33 US health systems. BMI categories were based on age- and sex-specific percentiles for youth (2-19 years) and World Health Organization cut points for adults (≥20 years). Trends in obesity and GLP1-RA prescriptions were characterized by BMI categories among youth and adults with T1D from 2008-2011 to 2020-2023. RESULTS:From 2008-2011 to 2020-2023, the prevalence of obesity among youth with T1D increased from 18.1% (95% confidence interval [CI], 17.3%-18.9%) to 26.0% (25.2%-26.8%) (p-for-trend < 0.001). Among adults with T1D, the prevalence of obesity rose from 30.5% (30.0%-31.0%) in 2008-2011 to 38.1% (37.8%-38.5%) in 2020-2023 (p-for-trend < 0.001). Obesity was highest in Black and Hispanic youth and adults, and racial and ethnic disparities persisted over time. Over the last 15-year period, GLP-1RA prescriptions significantly increased across all BMI categories in a dose-response manner among both youth and adults with T1D (all p-for-trend < 0.001). CONCLUSIONS:Over the last 15-year period, obesity has reached epidemic levels in US youth and adults with T1D, with significant disparities among racial and ethnic minoritized populations. These findings, coupled with the increase in GLP-1RA prescriptions, underscore the urgent need for data on GLP-1RAs' safety and effectiveness and guidance for obesity management in T1D.
PMCID:12049267
PMID: 40028670
ISSN: 1463-1326
CID: 5832872

Neighborhood Built Environment and Home Dialysis Utilization: Varying Patterns by Urbanicity-Dependent Patterns and Implications for Policy

Kim, Byoungjun; Li, Yiting; Lee, Myeonggyun; Bae, Sunjae; Blum, Matthew F; Le, Dustin; Coresh, Josef; Charytan, David M; Goldfarb, David S; Segev, Dorry L; Thorpe, Lorna E; Grams, Morgan E; McAdams-DeMarco, Mara A
RATIONALE & OBJECTIVE/OBJECTIVE:Despite national efforts, the uptake of home dialysis (peritoneal dialysis or home hemodialysis) remains low. Characteristics of the built environment may differentially impact home dialysis use. STUDY DESIGN/METHODS:Retrospective cohort study (2010-2019). SETTING & PARTICIPANTS/METHODS:1,103,695 adults (aged≥18 years) initiating dialysis in the US Renal Data System. EXPOSURE/METHODS:We examined 3 built environment domains based on residential ZIP code: (1) medically underserved areas (MUAs), defined as neighborhoods with limited primary care access; (2) distance to the nearest dialysis facility; and (3) distribution of housing characteristics (structure and overcrowding). OUTCOME/RESULTS:Uptake of home dialysis modalities at dialysis initiation. ANALYTICAL APPROACH/METHODS:We quantified associations between built environment characteristics and home dialysis initiation using multilevel logistic regression stratified by urbanicity type (urban, suburban, small-town, and rural). RESULTS:Among adults initiating dialysis, 40.8% lived in MUAs. Across ZIP codes, the mean percentage of overcrowded housing was 4.2% (SD, 4.7%), and the percentage of detached housing was 61.1% (SD, 21.1%); mean distance to the nearest dialysis facility was 5.5km (SD, 9.1km). Living in MUAs was associated with reduced home dialysis use only in urban (OR, 0.94; 95% CI, 0.91-0.96) and suburban (OR, 0.92; 95% CI, 0.89-0.94) areas. Similarly, housing overcrowding was associated with decreased home dialysis use only in urban (OR, 0.88; 95% CI, 0.86-0.89) and suburban (OR, 0.91; 95% CI, 0.90-0.93) areas. Longer distance to a dialysis facility was the most salient neighborhood factor associated with increased home dialysis use in small towns (OR, 1.14; 95% CI, 1.12-1.16) and rural areas (OR, 1.17; 95% CI, 1.15-1.19). LIMITATIONS/CONCLUSIONS:Housing characteristics were measured at the ZIP code level. CONCLUSIONS:Built environment characteristics associated with home dialysis uptake vary by urbanicity. Policies should address built environment barriers that are specific to urbanicity level. For example, increasing the frequency of dialysate delivery schedules could address housing space constraints in urban and suburban areas, and promoting home dialysis might be more effective for patients living far from dialysis centers in small-town and rural areas.
PMID: 40081754
ISSN: 1523-6838
CID: 5852612

Real-World Evidence Linking the Predicting Risk of Cardiovascular Disease Events Risk Score and Coronary Artery Calcium

Rhee, Aaron J; Pandit, Krutika; Berger, Jeffrey S; Iturrate, Eduardo; Coresh, Josef; Khan, Sadiya S; Shin, Jung-Im; Hochman, Judith S; Reynolds, Harmony R; Grams, Morgan E
PMID: 40396415
ISSN: 2047-9980
CID: 5853092

Polypharmacy and Potentially Inappropriate Medications in Adults ≥75 Years of Age by Dementia and Frailty Status: The ARIC Study

Lutsey, Pamela L; Misialek, Jeffrey R; Whitsel, Eric A; Lakshminarayan, Kamakshi; Kucharska-Newton, Anna M; Windham, B Gwen; Sullivan, Kevin J; Secora, Alex; Grams, Morgan E; Farley, Joel F
OBJECTIVE:To estimate the prevalence of polypharmacy (concomitant use of ≥5 medications), hyperpolypharmacy (≥10 medications), and potentially inappropriate medication (PIM) use among older adults according to dementia and frailty status. PATIENTS AND METHODS/METHODS:Cross-sectional data (2016-2017) from 3912 participants aged 71 to 94 years (mean ± SD, 79.6±4.8 years; 59.2% female; 24.5% Black race) from the community-based Atherosclerosis Risk in Communities (ARIC) study were used. Dementia and mild cognitive impairment status was based on comprehensive neurocognitive assessment, informant interviews, and adjudication by an expert panel. Participants were classified as frail, prefrail, or robust according to the Fried frailty phenotype definition. Medication containers were brought to the clinic. The PIMs were defined using a modified version of the Beers Criteria. RESULTS:Polypharmacy, hyperpolypharmacy, and PIM use were prevalent in 67.1%, 18.8%, and 23.9% of participants, respectively, and 7.9% were classified as having dementia and 8.0% as frail. The demographic-adjusted relative risk ratio (95% CI) for participants with dementia vs normal cognition was 1.79 (1.27 to 2.51) for hyperpolypharmacy, and the odds ratio (95% CI) for PIM use was 1.58 (1.21 to 2.06). The relative risk ratios (95% CIs) for hyperpolypharmacy were 8.35 (5.57 to 12.54) for frail and 2.70 (2.14 to 3.41) for prefrail compared with robust. CONCLUSION/CONCLUSIONS:Polypharmacy, hyperpolypharmacy, and PIM use were common in this community-based sample of adults approximately 80 years old. These patterns of use were even more common among participants with dementia and frailty, who are at elevated risk for adverse outcomes.
PMID: 40380972
ISSN: 1942-5546
CID: 5844902

Validation of an Algorithm to Identify End-Stage Kidney Disease in Electronic Health Records Data

Gao, Chenxi; Xu, Yunwen; Mehta, Sneha; Sang, Yingying; Flaherty, Carina; Surapaneni, Aditya; Pandit, Krutika; Chang, Alexander R; Green, Jamie Alton; Grams, Morgan E; Shin, Jung-Im
RATIONALE & OBJECTIVES/OBJECTIVE:Accurate ascertainment of end-stage kidney disease (ESKD) in electronic health records (EHRs) data is important for much epidemiological research. This study aimed to develop and validate an algorithm using diagnosis and procedure codes to identify patients with ESKD (treated with maintenance dialysis or kidney transplantation) in EHRs data. STUDY DESIGN/METHODS:Study of diagnostic algorithms. SETTING & PARTICIPANTS/METHODS:The development cohort included 559,615 patients treated at the Geisinger Health System (January 1996-June 2018). The validation cohort included 767,186 patients treated at New York University Langone Health System (January 2018-December 2020). ALGORITHMS COMPARED/UNASSIGNED:An algorithm developed using diagnosis and procedure codes compared to a nominal gold standard designation within the United States Renal Data System (USRDS) data. The performance of the algorithm was characterized by sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). The dates of incident ESKD between the algorithm and USRDS were compared in a subset of cases. OUTCOMES/RESULTS:ESKD (maintenance dialysis, prior recipient of a kidney transplant, or kidney transplantation surgery) cases. RESULTS:In Geisinger, we developed the ESKD algorithm that identified 4,766 (0.85%) ESKD cases, while there were 5,155 (0.92%) ESKD cases reported by the USRDS. The sensitivity, specificity, PPV, and NPV of the algorithm were 73.9% (95% CI, 72.7-75.1%), 99.83% (99.82-99.84%), 79.9% (78.9-81.0%), and 99.76% (99.75-99.77%), respectively. When applying the algorithm to New York University Langone Health System data, the sensitivity, specificity, PPV, and NPV were 71.8% (95% CI, 70.7-73.0%), 99.95% (99.95-99.96%), 91.6% (90.8-92.4%), and 99.79 (99.78-99.80%), respectively. The median (interquartile range) difference between dates of incident ESKD (algorithms minus USRDS) were -3 (-21 to 83) days in Geisinger and 0 (-12 to 69) days in New York University Langone Health. LIMITATIONS/CONCLUSIONS:Use of structured EHRs data only. CONCLUSIONS:Algorithms combining diagnosis and procedure codes show high specificity and modest sensitivity for identifying patients with ESKD, providing a research tool to inform future EHR-based studies.
PMID: 40381931
ISSN: 1523-6838
CID: 5852622

Fitbit-measured physical activity is inversely associated with incident atrial fibrillation among All of Us participants

Barua, Souptik; Upadhyay, Dhairya; Surapaneni, Aditya; Grams, Morgan; Jankelson, Lior; Heffron, Sean
BACKGROUND:Individuals who report meeting weekly moderate to vigorous physical activity (MVPA) guidelines have lower risk of atrial fibrillation (AF). However existing studies have relied on subjective questionnaires or short-duration (<1 week) objective assessments using accelerometry. The objective of this research was to investigate an association between MVPA levels and the incidence of AF, utilizing long-term, free-living accelerometry data. METHODS:1-year Fitbit data, in addition to survey and electronic health record (EHR) data, were extracted from the NIH All of Us (AoU) research database. Cox proportional hazards regression was used to model the association of average MVPA and incident AF over a five-year follow-up period. RESULTS:, 41±12 complete weeks of Fitbit wear). 97 individuals (0.6%) experienced incident AF in the five-year follow-up period. Every additional hour of MVPA was associated with 8% lower AF risk (HR = 0.92 [0.86,0.99], p=0.02). In a subset of 10533 participants with genomic data, this association persisted after adjustment for AF genetic risk score. CONCLUSIONS:Higher amounts of objectively measured MVPA, measured using free-living, long-term accelerometry data, were inversely associated with risk of incident AF, independent of clinical and genetic risk factors.
PMID: 40379038
ISSN: 1097-6744
CID: 5844822